A new market study, titled “Global Oncolytic Virus Therapy Market Research and Forecast, 2018-2023” has been featured on WiseGuyReports.
Oncolytic virus therapy is based on the treatment through a virus that infects and kills cancer cells. These oncolytic viruses not only destroy the cancerous cell, also prevents the growth of tumor cells by stimulating the host anti-tumor immune responses. The first oncolytic virus therapy was approved in 2015, it is still is in the nascent stage of being considered as suitable and effective cancer therapy. The first oncolytic virus was the genetically modified herpes simplex virus type I that is Talimogene laherparepvec (T-VEC) that reported to be clinically beneficial for patients with melanoma.
Oncolytic virus therapy market is anticipated to grow at a decent growth rate during the forecast period. Most of the oncolytic virus therapy in clinical trials are in preclinical phase followed by Phase-I trials. At present, two three oncolytic drugs have been commercialized, however, approximately 48 oncolytic virus therapies are in clinical trials. The factors that are fueling the growth of the market includes higher incidence and prevalence rate of cancer. Melanoma is one of the cancers that has been prevalent across the US region. The first oncolytic virus success over chemotherapy and radiotherapy have paved ways for developing them for other cancers. The other factors are the side effects associated with conventional cancer therapies. Chemotherapy and radiation therapy cause certain side-effects such as prolonged exposure to radiation may cause skin cancer.
Global oncolytic virus therapy market is segregated on the basis of the geographical regions that are contributing significantly towards the growth of the market. On the basis of the geography, market is segmented into North America, Europe, Asia Pacific and Rest of the World. North America is the dominant market in the oncolytic virus immunotherapy market, globally. R&D in oncolytic virus therapy and cohesive government policies will boost innovative cancer therapies. Europe followed by APAC region are considered to be lucrative regions for the growth of oncolytic virus market owing to larger patient base and adoption for novel immunotherapies.
Major global oncolytic virus therapy market players such as Amgen, Oncolytics Biotech, Viralytics, Transgene SA, Oncolys BioPharma, Targovax, PsiOxus Therapeutics and so on are contributing significantly into the market growth. Various corporate strategies such as investment in R&D are contributing into the market growth of oncolytic virus therapy market. For instance, Merck announced to invest $394 million for Viralytics, recently in February 2018, which is a company based in Australia for the development of oncolytic viruses to further boost the cancer immunotherapy pembrolizumab (Keytruda).
The market study of global oncolytic virus therapy market is incorporated by extensive primary and secondary research conducted by research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include
- Financial reports of companies involved in the market
- Whitepapers such as research-papers and news blogs
- Company websites and their product catalogue.
The report is intended for researchers in healthcare segment, Investing companies, Government Organizations for overall market analysis and competitive analysis. The report provides in-depth analysis on market size, growth opportunity in market, product types. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
THE REPORT COVERS
- Comprehensive research methodology of global oncolytic virus therapy market.
- In-depth analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the global oncolytic virus therapy market.
- Insights about market determinants which are stimulating the global oncolytic virus therapy market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
- BioVex Inc.,
- Cold Genesys, Inc.
- Crusade Laboratories
- Cynvec LLC
- Genelux Corp.
- JennerRex Co. Ltd
- Lokon Pharma AB
- MediGene AG
- Neotropix, Inc.
- Oncolys BioPharma
- Oncolytics Biotech, Inc.
- Otsuka Pharmaceuticals Co. Ltd
- PsiOxus Therapeutics Ltd
- Shanghai Sunway Biotech Co. Ltd
- Silajen Biotherapeutics, Inc.
- Sorrento Therapeutics
- SunWay Biotech Co. Ltd
- Takara Bio, Inc.
- TILT Biotherapeutics
- Transgene SA
- VCN Biosciences SL
- Viralytics Ltd
Table of Content
CHAPTER 1. Report Summary
CHAPTER 2. Market Overview and Insights
CHAPTER 3. Market Determinant
CHAPTER 4. Market Segmentation
CHAPTER 5. Competitive Landscape
CHAPTER 6. Regional Analysis
CHAPTER 7. Company Profiles
Wise Guy Reports is part of the Wise Guy Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)